欧康维视生物-B(01477.HK) 公布2024年度营运数据,收益介乎4.08亿至4.2亿人民币,较2023年度增加65.6%-70.5%。收益大幅增长主要由于公司完成Alcon转让产品的收购及获许可产品的授权引进,显著提升收益规模;及销售其他眼科医药产品产生的收益大幅增加。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-12 16:25。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/08/12 | 中期业绩 | 无派息 |
2024/03/21 | 末期业绩 | 无派息 |
2023/08/24 | 中期业绩 | 无派息 |
2023/03/30 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.